Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 289

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Three-arm Phase III Trial Comparing Cisplatin Plus 5-FU (CF) Versus Docetaxel, Cisplatin Plus 5-FU (DCF) Versus Radiotherapy with CF (CF-RT) as Preoperative Therapy for Locally Advanced Esophageal Cancer (JCOG1109, NExT Study)

Nakamura, Kenichi, Kato, Ken, Igaki, Hiroyasu, Ito, Yoshinori, Mizusawa, Junki, Ando, Nobutoshi, Udagawa, Harushi, Tsubosa, Yasuhiro, Daiko, Hiroyuki, Hironaka, Shuichi, Fukuda, Haruhiko, Kitagawa, Yuko, on behalf of the Japan Esophageal Oncology Group/Japan Clinical Oncology Group·2013·Japanese Journal of Clinical Oncology

Abstract

A three-arm Phase III trial was started in November 2012. Preoperative chemotherapy with cisplatin plus 5-fluorouracil is the current standard treatment for locally advanced esophageal cancer in Japan, while preoperative chemoradiotherapy with cisplatin plus 5-fluorouracil is the standard in Western countries. Preoperative chemotherapy with docetaxel, cisplatin plus 5-fluorouracil is another promising regimen. The purpose of this study is to confirm the superiority of docetaxel, cisplatin plus 5-fluorouracil over cisplatin plus 5-fluorouracil and the superiority of cisplatin plus 5-fluorouracil with chemoradiotherapy over cisplatin plus 5-fluorouracil as preoperative therapy for squamous cell carcinoma of esophagus. A total of 501 patients will be accrued from 41 Japanese institutions within 6.25 years. The primary endpoint is overall survival and the secondary endpoints include progression-free survival, %R0 resection, response rate, pathologic complete response rate and adverse events.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jjco/hyt061

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 289

Metadata

Authors
Nakamura, K., Kato, K., Igaki, H., Ito, Y., Mizusawa, J., Ando, N., Udagawa, H., Tsubosa, Y., Daiko, H., Hironaka, S., Fukuda, H., Kitagawa, Y., & on behalf of the Japan Esophageal Oncology Group/Japan Clinical Oncology Group
Venue
Japanese Journal of Clinical Oncology
Published
2013-04-26
Volume
43
Issue
7
Pages
752-755
ISSN
  • 0368-2811 (ISSN-L)
  • 1465-3621
OpenAlex
W2123279461
Cited by
289
References
7
FWCI
11.38
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Three-arm Phase III Trial Comparing Cisplatin Plus 5-FU (CF) Versus Docetaxel, Cisplatin Plus 5-FU (DCF) Versus Radiotherapy with CF (CF-RT) as Preoperative Therapy for Locally Advanced Esophageal Cancer (JCOG1109, NExT Study). https://app.cochat.ai/papers/10.1093/jjco/hyt061
The paper
Nakamura, K., Kato, K., Igaki, H., Ito, Y., Mizusawa, J., Ando, N., Udagawa, H., Tsubosa, Y., Daiko, H., Hironaka, S., Fukuda, H., Kitagawa, Y., & on behalf of the Japan Esophageal Oncology Group/Japan Clinical Oncology Group. (2013). Three-arm Phase III Trial Comparing Cisplatin Plus 5-FU (CF) Versus Docetaxel, Cisplatin Plus 5-FU (DCF) Versus Radiotherapy with CF (CF-RT) as Preoperative Therapy for Locally Advanced Esophageal Cancer (JCOG1109, NExT Study). Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyt061

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.